Evidence map›Paper›PMID 37967363›Full record

ArticleCancer research2024

R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription-Replication Conflicts.

Zhiyan Silvia Liu, Sayantani Sinha, Maxwell Bannister, Axia Song, Erica Arriaga-Gomez, Alexander J McKeeken, Elizabeth A Bonner, Benjamin K Hanson, Martina Sarchi, Kouhei Takashima and 20 more

Open access · greenAbstract read
In one paragraph

Article in Cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. TargetingGenes & development · 2026
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Transcription-Coupled Repair and R-Loop Crosstalk in Genome Stability.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 9 institutions in 4 countries.

Zhiyan Silvia Liu *Molecular Pharmacology and Therapeutics Graduate Program, Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0001-5902-9375
Sayantani Sinha *Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0001-6637-9541
Maxwell BannisterMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0002-8528-2638
Axia SongTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0009-0002-9176-2387
Erica Arriaga-GomezTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0002-8237-6751
Alexander J McKeekenMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0001-7470-704X
Elizabeth A BonnerTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0001-5050-8652
Benjamin K HansonMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0003-1757-9429
Martina SarchiDivision of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Minnesota.ORCID 0000-0002-1557-6577
Kouhei TakashimaDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0009-0006-6170-8266
Dawei ZongMolecular Pharmacology and Therapeutics Graduate Program, Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota.ORCID 0009-0002-0397-4102
Victor M CorralMolecular Pharmacology and Therapeutics Graduate Program, Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0002-2385-2519
Evan NguyenTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0009-0007-9276-4145
Jennifer YooMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0009-0005-0258-9167
Wannasiri ChiraphapphaiboonMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0002-4244-4895
Cassandra LeibsonMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0009-0002-8516-7178
Matthew C McMahonMolecular Pharmacology and Therapeutics Graduate Program, Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota.ORCID 0009-0009-5990-2635
Sumit RaiMassachusetts General Hospital Cancer Center, Charlestown, Massachusetts.ORCID 0000-0003-1260-7849
Elizabeth M SwisherDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, Washington.ORCID 0000-0003-2331-0434
Zohar SachsMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0001-9386-4163
Srinivas ChatlaFels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania.ORCID 0000-0002-8509-8494
Derek L StirewaltTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0003-4151-3171
H Joachim DeegClinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0002-4426-9023
Tomasz SkorskiFels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania.ORCID 0000-0002-3809-4538
Eirini P PapapetrouDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0000-0001-7002-417X
Matthew J WalterDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0002-7753-1091
Timothy A GraubertMassachusetts General Hospital Cancer Center, Charlestown, Massachusetts.ORCID 0000-0002-7710-1171
Sergei DoulatovDivision of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Minnesota.ORCID 0000-0002-1328-364X
Stanley C LeeTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0001-7110-2416
Hai Dang NguyenMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0002-4200-8778
University of Minnesota · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAMassachusetts General Hospital · USTemple University · USTisch Hospital · USUniversity of Washington · USCalifornia Institute for Regenerative Medicine · USFred Hutch Cancer Center · USWashington University in St. Louis · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
Targeting the Bone Marrow Microenvironment In Acute Lymphocytic LeukemiaP50CA171963 · NCI · WASHINGTON UNIVERSITY · PI Daniel C Link · 2013 to 2026
$31.6M
UNIVERSITY OF MINNESOTA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE (UMN CTSI)UL1RR033183 · NCRR · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2011 to 2011
$8.9M
Institutional Career Development CoreKL2TR002492 · NCATS · UNIVERSITY OF MINNESOTA · PI INGBAR, DAVID H · 2018 to 2022
$6.3M
Functional and molecular consequences of SF3B1 mutations in human hematopoietic stem cellsR01HL151651 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Robert K Bradley, Sergei Doulatov · 2020 to 2026
$4.0M
Mechanisms and therapeutic implications of human clonal hematopoiesis (CH) mutationsR01CA271331 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Eirini Papapetrou · 2022 to 2026
$3.3M
Impact of mutational order on molecular mechanisms of oncogenesisR01CA260711 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Eirini Papapetrou · 2022 to 2026
$3.2M
Mechanisms and targeting of aberrant Gas activation in myeloid neoplasmsR01CA271418 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Eirini Papapetrou · 2023 to 2026
$2.7M
Implications of PARP1 in myelodysplastic syndromes and targeted therapyR01HL163011 · NHLBI · UNIVERSITY OF MINNESOTA · PI Dang Hai Nguyen · 2022 to 2026
$2.5M
Uncovering epigenetic barriers to hematopoietic stem cell formationDP2HL147126 · NHLBI · UNIVERSITY OF WASHINGTON · PI DOULATOV, SERGEI · 2018 to 2018
$2.3M
The role of lamin B1 in normal and myelodysplastic hematopoiesisR01HL169156 · NHLBI · UNIVERSITY OF WASHINGTON · PI Sergei Doulatov · 2023 to 2026
$2.1M
NCATS NIH HHS KL2 TR002492NCATS NIH HHS UL1 TR002494NCI NIH HHS K99 CA218896NCI NIH HHS P30 CA015704NCI NIH HHS P50 CA171963NCI NIH HHS R00 CA218896NCI NIH HHS R01 CA244044NCI NIH HHS R01 CA247707NCI NIH HHS R01 CA260711NCI NIH HHS R01 CA271331NCI NIH HHS R01 CA271418NCRR NIH HHS UL1 RR033183NHLBI NIH HHS DP2 HL147126NHLBI NIH HHS R01 HL151651NHLBI NIH HHS R01 HL163011NHLBI NIH HHS R01 HL169156NIH HHS S10 OD028685ODCDC CDC HHS S10 OD028685
6 · The paper itself

Abstract

RNA splicing factor (SF) gene mutations are commonly observed in patients with myeloid malignancies. Here we showed that SRSF2- and U2AF1-mutant leukemias are preferentially sensitive to PARP inhibitors (PARPi), despite being proficient in homologous recombination repair. Instead, SF-mutant leukemias exhibited R-loop accumulation that elicited an R-loop-associated PARP1 response, rendering cells dependent on PARP1 activity for survival. Consequently, PARPi induced DNA damage and cell death in SF-mutant leukemias in an R-loop-dependent manner. PARPi further increased aberrant R-loop levels, causing higher transcription-replication collisions and triggering ATR activation in SF-mutant leukemias. Ultimately, PARPi-induced DNA damage and cell death in SF-mutant leukemias could be enhanced by ATR inhibition. Finally, the level of PARP1 activity at R-loops correlated with PARPi sensitivity, suggesting that R-loop-associated PARP1 activity could be predictive of PARPi sensitivity in patients harboring SF gene mutations. This study highlights the potential of targeting different R-loop response pathways caused by spliceosome gene mutations as a therapeutic strategy for treating cancer. SIGNIFICANCE: Spliceosome-mutant leukemias accumulate R-loops and require PARP1 to resolve transcription-replication conflicts and genomic instability, providing rationale to repurpose FDA-approved PARP inhibitors for patients carrying spliceosome gene mutations.

Indexed as

LeukemiaSpliceosomesDNA RepairHumansPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsR-Loop StructuresRNA Splicing FactorsPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsRNA Splicing Factors

Identifiers

PMID37967363
PMCPMC10922727
OpenAlexW4388688283

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.